Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Operating Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Operating Expenses for 17 consecutive years, with $71.4 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 23.8% to $71.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $600.2 million through Dec 2025, up 87.8% year-over-year, with the annual reading at $600.2 million for FY2025, 87.8% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $71.4 million at Myriad Genetics, up from $71.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $388.6 million in Q2 2025, with the low at $47.8 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $93.3 million, with a median of $71.2 million recorded in 2025.
  • The sharpest move saw Other Operating Expenses plummeted 37.62% in 2024, then soared 360.43% in 2025.
  • Over 5 years, Other Operating Expenses stood at $107.8 million in 2021, then increased by 15.86% to $124.9 million in 2022, then dropped by 7.45% to $115.6 million in 2023, then decreased by 18.94% to $93.7 million in 2024, then fell by 23.8% to $71.4 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $71.4 million, $71.0 million, and $388.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.